Annual report [Section 13 and 15(d), not S-K Item 405]

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)

v3.25.1
SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
 12 Months Ended
Jul. 02, 2021
Dec. 31, 2024
Dec. 31, 2023
May 01, 2024
Jan. 17, 2019
Allowance for doubtful accounts   $ 0 $ 0    
Advertising costs   33,506 113,170    
Impairment of intellectual property $ 47,980 0 47,980    
Impairment loss     47,980    
Grant funding during the first year       $ 4,131,123 $ 2,842,430
Grant funding       11,029,977  
Grant funding during the second year       3,638,268 2,831,838
Grant funding during the third year       $ 3,260,586 3,453,367
Grant additional funding during the third year         $ 99,431
Deferred revenues related to grant   56,590 0    
Grant receivables   0 76,266    
Deferred income   0 0    
Grant income   1,473,276 932,996    
Research and development expenses   $ 1,482,877 $ 891,063    
Ownership percentage   50.00%      
Royalty obligations description   The Company accounted for royalty obligations as debt in accordance with ASC 470-10-25 and derived a debt discount, which is amortized using the straight line method over the expected life of the arrangement, which is 15 years. The Company has no obligation to repay the then outstanding balance if during the expected life of 15 years the treatment is discontinued      
Description of Non-Controlling Interest   Due to a management fee equal to 65% of the Medical Corporation’s gross collected monthly revenue, 65% of the Medical Corporation’s earnings was allocated to the Company, and 35% to the non-controlling interest. Due to the Company’s retaining 75.8% ownership of BioCorRx Pharmaceuticals, Inc., 75.8% of BioCorRx Pharmaceuticals, Inc.’s earnings was allocated to the Company, and 24.2% to the non-controlling interest      
Royalty obligations, net   $ 7,171,200      
Minimum [Member]          
Property plant and equipment estimated useful lives   5 years      
Maximum [Member]          
Property plant and equipment estimated useful lives   15 years